ConductScience.org, home

Paper39620653

Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.

Röth A and 3 others. Immunotherapy, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape. Papers, record 39620653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39620653

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.
PubMed
Journal
Immunotherapy
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.6, provisional
iCite
Revised in PubMed
2025-06-03
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Röth AAlexanderhttps://orcid.org/0000-0003-4414-7699
2Kulasekararaj AGAustin Ghttps://orcid.org/0000-0003-3180-3570
3Scheinberg PPhilliphttps://orcid.org/0000-0002-9047-4538
4Nishimura JIJun-Ichihttps://orcid.org/0000-0001-5026-693X

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hemoglobinuria, ParoxysmalMajor topic
Complement C5Major topic
Antibodies, Monoclonal, HumanizedMajor topic
Complement Inactivating AgentsMajor topic
Humans

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137321625Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.Eur J Haematol2023https://conductscience.org/library/papers/37321625PubMed
220824457Epidemiology of rare anaemias in Europe.Adv Exp Med Biol2010https://conductscience.org/library/papers/20824457PubMed
332713742Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria.Hematol Transfus Cell Ther2021https://conductscience.org/library/papers/32713742PubMed
430171728Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel.Eur J Haematol2018https://conductscience.org/library/papers/30171728PubMed
535608260Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.Br J Haematol2022https://conductscience.org/library/papers/35608260PubMed
639535306Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies.Eur J Haematol2025https://conductscience.org/library/papers/39535306PubMed
737421604Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.Am J Hematol2023https://conductscience.org/library/papers/37421604PubMed
837655691The cost-effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA.J Comp Eff Res2023https://conductscience.org/library/papers/37655691PubMed
924161035Overview of complement activation and regulation.Semin Nephrol2013https://conductscience.org/library/papers/24161035PubMed
1018055865Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.Blood2008https://conductscience.org/library/papers/18055865PubMed
1137405515Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.J Patient Rep Outcomes2023https://conductscience.org/library/papers/37405515PubMed
1228439081Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.Sci Rep2017https://conductscience.org/library/papers/28439081PubMed
1328516949Paroxysmal nocturnal haemoglobinuria.Nat Rev Dis Primers2017https://conductscience.org/library/papers/28516949PubMed
1430510079Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.Blood2019https://conductscience.org/library/papers/30510079PubMed
1536848639Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.Blood Adv2023https://conductscience.org/library/papers/36848639PubMed
1631258525Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.Front Immunol2019https://conductscience.org/library/papers/31258525PubMed
1736594182Paroxysmal nocturnal hemoglobinuria: Where we stand.Am J Hematol2023https://conductscience.org/library/papers/36594182PubMed
1838924124Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.Am J Hematol2024https://conductscience.org/library/papers/38924124PubMed
1921460245Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.Blood2011https://conductscience.org/library/papers/21460245PubMed
2026839475Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.J Korean Med Sci2016https://conductscience.org/library/papers/26839475PubMed

See all 54 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
41809517Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease.J Blood Med2026https://conductscience.org/library/papers/41809517PubMed
41503194Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.Kidney Med2026https://conductscience.org/library/papers/41503194PubMed
41255851Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders.J Blood Med2025https://conductscience.org/library/papers/41255851PubMed
40868216Monoclonal Antibodies (mAbs) and Proteins: The Biologic Drugs Approved by the Food and Drug Administration (FDA) in 2024.Biomedicines2025https://conductscience.org/library/papers/40868216PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39620653

GET https://conductscience.org/api/papers/v1/39620653/references?page=2